Thu, Jul 31, 2014, 1:02 AM EDT - U.S. Markets open in 8 hrs 28 mins


% | $
Click the to save as a favorite.

Navidea Biopharmaceuticals, Inc Message Board

  • fincheck100 fincheck100 Jun 11, 2013 11:06 AM Flag

    No matter whatever the news ... no volume?

    I have no idea why the volume is so low? no matter whatever the news is, the volume is so low. I understand the shorts are manipulating this stock but manipulating the volume as well?

    81k sold so far as of 11:05 am eastern time... what news it is needed for this cr*p to take off??

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Positive Publication news for Lymphoseek has no major' surprises so stock doesnt react that much.
      Lymphoseek sales,EU partnership,officialy ending the H&N trial are some of the material events that should have better results in the rise of share price..
      Just a matter of time.

    • its obvious this stock is dead. The whole thing has been a bunch of nonsense from the start. All those analysts dont have a clue lifetech, JMP, all said 5-7 on approval, not one has explained why its 2.43. The analysts did not say 6-12 months after approval they said on approval. What is taking so long for the Euro partner another piece of news that supposed to help, I doubt it will. If the market loved NAVB there would be more volume and more buyers at 2.43, but there isn't. You cannot blame the shorts for no volume and no buying interest. I guess the market doesn't like this product or they think it will fail or require cash from stock offerings. This is hanging over the share price not letting it move. This is the only logical explanation.

    • ITS GONNA BE YEARS. This is the worst stock

1.320.00(0.00%)Jul 30 4:02 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.